

33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts

Overview:

This meeting marks the half waypoint for this cycle of the EDRN. Presentation by the EDRN PIs will provide NCI Program Staff with updates on progress made by individual researchers and by the EDRN as a collaborative network. This information will help NCI evaluate the network, plan for its future, and address questions such as: is this the optimal structure and what changes, if any, could be made to improve its productivity?

Wednesday September 5, 2018

7:00 a.m. – 8:00 a.m.

Riverfront Foyer

Sign-In and Continental Breakfast

8:00 a.m. – 8:10 a.m.

Riverfront Room

Opening of Steering Committee Meeting and Approval of Minutes for September 2017 Steering Committee Meeting

Joshua LaBaer, M.D., Ph.D., Arizona State University/The Biodesign Institute

8:10 a.m. – 8:30 a.m.

NCI Updates and Expectations for the Meeting

Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

8:30 a.m. – 3:00 p.m.

Collaborative Group Meetings (Concurrent Sessions)

Each BDL, CVC, BRL and the DMCC will present the progress made on their individual projects including set aside projects that are not part of a larger team project. The final three slides for each presentation should be

- Research highlights & list of publications
- Challenges and help needed to complete their projects
- Outlook and plans for the future
- Patents, Licenses, and International Collaborations

The lead PI of each team project or the PI of a CORE fund supported trial or biospecimen collection will present the progress of that project. The final three slides for each presentation should be

- Research highlights & list of publications
- Challenges and help needed to complete their projects
- Outlook and plans for the future
- Patents, Licenses, and International Collaborations

Each presentation will be approximately 15 minutes followed by 10 minutes for discussion. At the end of the session there will be a general discussion and identification of three or four critical questions for each type of cancer.

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018 (Continued)

- 3:00 p.m. – 3:30 p.m.
Riverfront Room Breast Tumor Evolution
Kornelia Polyak, MD., Ph.D., Dana-Farber Cancer
Institute
- 3:30 p.m. – 4:00 p.m. Activity-based Biomarkers for Noninvasive Cancer
Detection
Sangeeta Bhatia, M.D., Ph.D., Massachusetts
Institute of Technology
- 4:00 p.m. – 4:20 p.m. Data Management and Coordinating Center
Ziding Feng, Ph.D., Mark Thornquist, Ph.D., and
Margaret Pepe, Ph.D., Fred Hutchinson Cancer
Research Center
- 4:20 p.m. – 4:40 p.m. National Institute of Standards & Technology
Anne Plant, Ph.D., National Institute of Standards
& Technology
- 4:40 p.m. – 5:00 p.m. Informatics Center
Dan Crichton, M.S., NASA Jet Propulsion
Laboratory
- 5:00 p.m. – 5:20 p.m. Pacific Northwest National Laboratory: Use of
Novel Proteomic Approaches for Cancer
Biomarker Identification and Verification
Tao Liu, Ph.D., and Karin Rodland, Ph.D., Pacific
Northwest National Laboratory
- 5:20 p.m. – 6:30 p.m.**
Riverfront Room **EDRN Leadership Meeting**
○ EDRN Chair and Co-Chair
○ Collaborative Group Chairs and Co-Chairs
Based on presentations and discussions of the
Collaborative Group Meetings, the Collaborative
Group Chairs and Co-Chairs will briefly discuss 3
or 4 critical questions for each cancer. These
questions will be presented to the entire Steering
Committee Meeting on Thursday.
- 6:30 p.m.** **Adjourn for the Day**

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018

8:30 a.m. – 3:00 p.m.
Riverfront Room

Gastrointestinal Cancers Collaborative Group Meeting

Pancreatic Cancer

8:30 a.m. – 8:45 a.m.

New Plasma Biomarker sTRA Blinded Validation Performance Exceeds the Diagnostic Accuracy of CA19-9 in Pancreatic Cancer

- Brian Haab, Ph.D., Van Andel Research Institute
- Peter Allen, M.D., Memorial Sloan Kettering Cancer Center
- Randall Brand, M.D., University of Pittsburgh

8:45 a.m. – 8:55 a.m.

Q&A

8:55 a.m. – 9:10 a.m.

Current Status of Mucins and Associated Marker(s) for Early Detection and Risk Stratification of Benign and Malignant Pancreatic Diseases: Step Towards Clinical Application

- Randal Brand, M.D., University of Pittsburgh
- Surinder Batra, Ph.D., University of Nebraska Medical Center

9:10 a.m. – 9:20 a.m.

Q&A

9:20 a.m. – 9:35 a.m.

Integrative Biomarker Analysis for Early Detection of Pancreatic Cancer

Anirban Maitra, M.B.B.S., The University of Texas MD Anderson Cancer Center

9:35 a.m. – 9:45 a.m.

Q&A

9:45 a.m. – 10:00 a.m.

Team Project 1: Bake-off Study of Investigators from the Alliance of Pancreatic Cancer Consortia

Aatur Singhi, M.D., Ph.D., University of Pittsburgh

10:00 a.m. – 10:10 a.m.

Q&A

33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts

Wednesday September 5, 2018

Gastrointestinal Cancers Collaborative Group Meeting (Continued)

Pancreatic Cancer (Continued)

10:10 a.m. – 10:25 a.m.
Riverfront Room

Team Project 2: Validating Multiple EDRN PDAC Biomarkers on a Common Testing Set- Preliminary Findings

- Randall Brand, M.D., University of Pittsburgh
- Ying Huang, Ph.D., Fred Hutchinson Cancer Research Center

10:25 a.m. – 10:35 a.m.

Q&A

10:35 a.m. – 10:45 a.m.

Nanoplasmonic Quantification of Tumor-derived Circulating Extracellular Vesicles

Associate Member: Jia Fan, Ph.D., Arizona State University/The Biodesign Institute

10:45 a.m. – 10:50 a.m.

Q&A

Colon and Esophageal Cancers

10:50 a.m. – 11:05 a.m.

Biomarkers for Early Detection of GI Neoplasias

- Sanford Markowitz, M.D., Ph.D., Case Western Reserve University
- William Grady, M.D., Fred Hutchinson Cancer Research Center
- Kishore Guda, Ph.D., Case Western Reserve University

11:05 a.m. – 11:15 a.m.

Q&A

11:15 a.m. – 11:30 a.m.

ctDNA for Screening for and Monitoring of CRC

- Robert Schoen, M.D., M.P.H., University of Pittsburgh
- Kenneth Kinzler, Ph.D., Johns Hopkins University School of Medicine

11:30 a.m. – 11:40 a.m.

Q&A

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018

Gastrointestinal Cancers Collaborative Group Meeting (Continued)

Colon and Esophageal Cancers (Continued)

*11:40 a.m. – 11:55 a.m.
Riverfront Room*

Validation of Colon Cancer Biomarkers
Dean Brenner, M.D., University of Michigan

11:55 a.m. – 12:05 p.m.

Q&A

12:05 p.m. – 12:25 p.m.

Validation of Early Detection Biomarkers for CRC
& Team Project 1: Testing Colon Cancer Markers
in FIT-Negative and FIT-Positive Colon Adenomas
and Cancers
Paul Lampe, Ph.D., Fred Hutchinson Cancer
Research Center

12:25 p.m. – 12:35 p.m.

Q&A

12:35 p.m. – 1:35 p.m.

Lunch (On Your Own)

1:35 p.m. – 1:50 p.m.

Team Project 2: Evaluation of ctDNA and
Aberrantly Methylated DNA Markers in a
Common, Plasma-based Reference Set
Robert Schoen, M.D., M.P.H., University of
Pittsburgh

1:50 p.m. – 2:00 p.m.

Q&A

2:00 p.m. – 2:50 p.m.

Discussion

- Robert Schoen, M.D., M.P.H., University of Pittsburgh
- Brian Haab, Ph.D., Van Andel Research Institute

2:50 p.m. – 3:00 p.m.

**Election of New Chairs/Co-chairs for
Collaborative Group**

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018

8:30 a.m. – 3:00 p.m.

Somerset Room

**Prostate Cancer and Urological Cancers
Collaborative Group**

8:30 a.m. – 8:45 a.m.

**Development of Protein Biomarkers in Post-DRE
Urine for Use in Liquid Biopsy of Prostate Cancer:
An Update**

- O. John Semmes, Ph.D., Eastern Virginia Medical School
- Thomas Kislinger, Ph.D., Princess Margaret Cancer Centre, University Health Network and University of Toronto
- Paul Boutros, Ph.D., Ontario Institute for Cancer Research

8:45 a.m. – 8:55 a.m.

Q&A

8:55 a.m. – 9:10 a.m.

**Leveraging the Transcriptome for the Early
Detection of Prostate Cancer**

- Arul Chinnaiyan, M.D., Ph.D., University of Michigan
- Scott Tomlins, M.D., Ph.D., University of Michigan

9:10 a.m. – 9:20 a.m.

Q&A

9:20 a.m. – 9:35 a.m.

**High Throughput Analysis of Prostate Samples
Reveals Protein Modifications Associated with
Cancer Aggressiveness**

- Hui Zhang, Ph.D., Johns Hopkins University School of Medicine
- Ruedi Aebersold, Ph.D., Institute for Molecular Systems Biology

9:35 a.m. – 9:45 a.m.

Q&A

9:45 a.m. – 10:00 a.m.

**Enhancing Prostate Cancer Detection from RNA
profiling to Molecular Imaging**

Martin Sanda, M.D., Emory University

10:00 a.m. – 10:10 a.m.

Q&A

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018

Prostate Cancer and Urological Cancers Collaborative Group (Continued)

- | | |
|--|---|
| <i>10:10 a.m. – 10:25 a.m.</i>
<i>Somerset Room</i> | <u>Enhancing Prostate Cancer Biomarkers for African American Men</u>
Shiv Srivastava, Ph.D., Center for Prostate Disease Research, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center |
| <i>10:25 a.m. – 10:35 a.m.</i> | Q&A |
| <i>10:35 a.m. – 10:50 a.m.</i> | <u>Identification of Candidate Biomarkers for Early Detection of Aggressive Prostate Cancer Using Targeted Proteomics</u>
Tao Liu, Ph.D., and Karin Rodland, Ph.D., Pacific Northwest National Laboratory |
| <i>10:50 a.m. – 11:00 a.m.</i> | Q&A |
| <i>11:00 a.m. – 11:15 a.m.</i> | <u>The EDRN BRL at Johns Hopkins: 2018 Research Project Updates</u>
Dan Chan, Ph.D., Johns Hopkins Medical Institutions |
| <i>11:15 a.m. – 11:25 a.m.</i> | Q&A |
| <i>11:25 a.m. – 11:40 a.m.</i> | <u>Restriction Spectrum Imaging to Improve Prostate MRI</u>
Associate Member: Michael Liss, M.D., M.A.S., University of Texas Health Science Center at San Antonio |
| <i>11:40 a.m. – 11:50 a.m.</i> | Q&A |
| <i>11:50 a.m. – 12:05 p.m.</i> | Team Project 1: <u>The Tissue Upgrading Study</u>
Robin Leach, Ph.D., University of Texas Health Science Center at San Antonio |
| <i>12:05 p.m. – 12:15 p.m.</i> | Q&A |

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018

Prostate Cancer and Urological Cancers Collaborative Group (Continued)

*12:15 p.m. – 12:30 p.m.
Somerset Room*

Team Project 2: EDRN Prostate MRI Biomarker Study, Reference Set and Longitudinal Testing of Validated Biomarkers
John T. Wei, M.D., University of Michigan

12:30 p.m. – 12:40 p.m.

Q&A

12:40 p.m. – 1:40 p.m.

Lunch (On Your Own)

1:40 p.m. – 2:50 p.m.

Discussion

- Martin Sanda, M.D., Emory University
- O. John Semmes, Ph.D., Eastern Virginia Medical School

2:50 p.m. – 3:00 p.m.

Election of New Chairs/Co-chairs for Collaborative Group

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018

8:30 a.m. – 3:00 p.m.

Charles A Room

**Lung and Upper Aerodigestive Cancers
Collaborative Group**

8:30 a.m. – 8:45 a.m.

Integration of Biomarker Signatures from
Peripheral Blood for Diagnosis, Prognosis,
Remission and Recurrence of Lung Cancer
Louis Showe, Ph.D., The Wistar Institute

8:45 a.m. – 8:55 a.m.

Q&A

8:55 a.m. – 9:10 a.m.

The Boston University-UCLA Lung Cancer
Biomarker Development Lab

- Steve Dubinett, M.D., University of California
Los Angeles
- David Elashoff, Ph.D., University of California
Los Angeles
- Marc Lenburg, Ph.D., Boston University
- Avrum Spira, M.D., M.Sc., Boston University

9:10 a.m. – 9:20 a.m.

Q&A

9:20 a.m. – 9:35 a.m.

Can Mesothelioma Be Diagnosed with Blood
Immunoprofiles?
Haining Yang, Ph.D., University of Hawaii Cancer
Center

9:35 a.m. – 9:45 a.m.

Q&A

9:45 a.m. – 10:00 a.m.

DNA Methylation Based Detection of Cancer

- Jeff Tza-Huei Wang, Ph.D., Johns Hopkins
University
- James Herman, M.D., University of Pittsburgh
Cancer Institute

10:00 a.m. – 10:10 a.m.

Q&A

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018

Lung and Upper Aerodigestive Cancers Collaborative Group (Continued)

<i>10:10 a.m. – 10:25 a.m.</i> <i>Charles A Room</i>	<u>Moffitt's Imaging Biomarker Validation Center (MIBVAC): Radiomics for Early Detection of Lung Cancer</u> Matthew Schabath, Ph.D., H. Lee Moffitt Cancer Center and Research Institute, Inc.
<i>10:25 a.m. – 10:35 a.m.</i>	Q&A
<i>10:35 a.m. – 10:50 a.m.</i>	<u>Validation of Biomarkers Assessing the Risk of Developing Lung Cancer</u> Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center
<i>10:50 a.m. – 11:00 a.m.</i>	Q&A
<i>11:00 a.m. – 11:15 a.m.</i>	<u>University of Maryland Baltimore Biomarker Reference Laboratory miRNA Expression in Non-Small Cell Lung Cancer as an Early Detection Biomarker</u> Sanford Stass, M.D., University of Maryland School of Medicine
<i>11:15 a.m. – 11:25 a.m.</i>	Q&A
<i>11:25 a.m. – 11:40 a.m.</i>	Team Project 1: <u>Biomarkers for Early Detection of Mesothelioma</u> Haining Yang, Ph.D., University of Hawaii Cancer Center
<i>11:40 a.m. – 11:50 a.m.</i>	Q&A

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018

Lung and Upper Aerodigestive Cancers Collaborative Group (Continued)

- 11:50 a.m. – 12:05 p.m.* Team Project 2b: Validating an Integrated Biomarker and Imaging Approach in the Evaluation of Indeterminate Pulmonary Nodules (IPNs)
Charles A Room Eric Grogan, M.D., Vanderbilt Medical Center
- 12:05 p.m. – 12:15 p.m.* Q&A
- 12:15 p.m. – 1:15 p.m.** **Lunch (On Your Own)**
- 1:15 p.m. – 2:50 p.m.* Discussion
○ Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center
○ Haining Yang, Ph.D., University of Hawaii Cancer Center
- 2:50 p.m. – 3:00 p.m.** **Election of New Chairs/Co-chairs for Collaborative Group**

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018

8:30 a.m. – 3:00 p.m.

Charles B Room

**Breast and Gynecological Cancers
Collaborative Group**

Breast Cancer

8:30 a.m. – 8:40 a.m.

A Unique Approach Combining Avatar Mice and Targeted Mass Spectrometry to Identify Blood Biomarkers for Early Detection of Breast Cancer
Michael Lewis, Ph.D., Baylor College of Medicine

8:40 a.m. – 8:50 a.m.

Q&A

8:50 a.m. – 9:00 a.m.

Improving Early Detection of Breast Cancer with Auto-Anti-Glycoprotein Antibodies
Joshua LaBaer, M.D., Ph.D., Arizona State University/The Biodesign Institute

9:00 a.m. – 9:10 a.m.

Q&A

9:10 a.m. – 9:20 a.m.

Resources for Diagnosing Breast Cancer

- Jeffrey Marks, Ph.D., Duke University Medical Center
- Cha-Mei Tang, Sc.D., Creatv MicroTech Inc.

9:20 a.m. – 9:30 a.m.

Q&A

9:30 a.m. – 9:40 a.m.

Phase 3 Validation of Early Detection Biomarkers for ER+ Breast Cancer
Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center

9:40 a.m. – 9:50 a.m.

Q&A

9:50 a.m. – 10:00 a.m.

H. Lee Moffitt Cancer Center CVC Breast Imaging Progress
John Heine, Ph.D., H. Lee Moffitt Cancer Center and Research Institute, Inc.

10:00 a.m. – 10:10 a.m.

Q&A

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018

Breast and Gynecological Cancers Collaborative Group (Continued)

Breast Cancer (Continued)

- | | |
|---|--|
| <i>10:10 a.m. – 10:20 a.m.</i>
<i>Charles B Room</i> | Team Project 1: <u>Identification of Biomarkers for Non-triple Negative Breast Cancer</u>
Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center |
| <i>10:20 a.m. – 10:30 a.m.</i> | Q&A |
| <i>10:30 a.m. – 10:40 a.m.</i> | Team Project 2: <u>Imaging Plus Biomarkers for the Diagnosis of Breast Cancer</u>
Jeffrey Marks, Ph.D., Duke University Medical Center |
| <i>10:40 a.m. – 10:50 a.m.</i> | Q&A |
| <i>10:50 a.m. – 11:00 a.m.</i> | Project 3: <u>A Unique Approach Combining Avatar Mice and Targeted Mass Spectrometry to Identify Blood Biomarkers for Early Detection of Breast Cancer</u>
Michael Lewis, Ph.D., Baylor College of Medicine |
| <i>11:00 a.m. – 11:10 a.m.</i> | Q&A |

Ovarian Cancer

- | | |
|--------------------------------|--|
| <i>11:10 a.m. – 11:20 a.m.</i> | <u>PapSEEK and PapDREAMing for Early Detection of Ovarian Cancer; Analysis of Proteomic Signatures</u> <ul style="list-style-type: none">○ Zhen Zhang, Ph.D., Johns Hopkins University School of Medicine○ Ie-Ming Shih, M.D., Ph.D., Johns Hopkins University School of Medicine |
| <i>11:20 a.m. – 11:30 a.m.</i> | Q&A |

33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts

Wednesday September 5, 2018

Breast and Gynecological Cancers Collaborative Group (Continued)

Ovarian Cancer (Continued)

<i>11:30 a.m. – 11:40 a.m.</i> <i>Charles B Room</i>	<u>Longitudinal Proteomic Pathways to Ovarian Cancer Biomarker Discovery</u> <ul style="list-style-type: none">○ Steven Skates, Ph.D., Massachusetts General Hospital○ Michael Gillette, M.D., Ph.D., Broad Institute at MIT and Harvard
<i>11:40 a.m. – 11:50 a.m.</i>	Q&A
<i>11:50 a.m. – 12:00 p.m.</i>	<u>New Biomarkers to Improve Early Detection of Ovarian Cancer</u> Robert Bast, M.D., The University of Texas MD Anderson Cancer Center
<i>12:00 p.m. – 12:10 p.m.</i>	Q&A
<i>12:10 p.m. – 12:20 p.m.</i>	<u>Phase 2 and 3 Validation of Auto-Antibodies as Early Detection Biomarkers for Serous Ovarian Cancer</u> Charles Drescher, M.D., Fred Hutchinson Cancer Research Center
<i>12:20 p.m. – 12:30 p.m.</i>	Q&A
12:30 p.m. – 1:30 p.m.	Lunch (On Your Own)
<i>1:30 p.m. – 1:40 p.m.</i>	Team Project 1: <u>Circulating Autoantibody Biomarkers for Early Detection of Ovarian Cancer</u> Robert Bast, M.D., The University of Texas MD Anderson Cancer Center
<i>1:40 p.m. – 1:50 p.m.</i>	Q&A

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Wednesday September 5, 2018

Breast and Gynecological Cancers Collaborative Group (Continued)

Ovarian Cancer (Continued)

1:50 p.m. – 2:00 p.m.
Charles B Room

Team Project 2: Ovarian Team Project: Ovarian Cancer Detection by Plasma Proteins and Uterine Lavage
Steven Skates, Ph.D., Massachusetts General Hospital

2:00 p.m. – 2:10 p.m.

Q&A

2:10 p.m. – 2:50 p.m.

Discussion

- Steven Skates, Ph.D., Massachusetts General Hospital
- Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center

2:50 p.m. – 3:00 p.m.

Election of New Chairs/Co-chairs for Collaborative Group

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Thursday September 6, 2018

Reports from the Collaborative Groups

The Chair or Co-Chair will provide a brief overview of the research being conducted by that group and identify critical questions and gaps in the field. There will then be three presentations by different PIs and a discussion of the critical questions identified the previous day.

7:00 a.m. – 8:00 a.m.

Riverfront Foyer

Sign-in/Continental Breakfast

8:00 a.m. – 9:40 a.m.

Riverfront Room

Report from Gastrointestinal Cancers Collaborative Group

8:00 a.m. – 8:20 a.m.

Salient Report from the Chair/Co-Chair

8:20 a.m. – 8:40 a.m.

Presenter 1

8:40 a.m. – 9:00 a.m.

Presenter 2

9:00 a.m. – 9:20 a.m.

Presenter 3

9:20 a.m. – 9:40 a.m.

Discussion of the Critical Questions

- Collaborative Group Chair
- Member of the EDRN Executive Committee
- EDRN PI with content expertise (not necessarily the organ expertise)

9:40 a.m. – 9:50 a.m.

Thoughts on the Nature of Neoplasia

Larry Norton, M.D., Memorial Sloan-Kettering Cancer Center

9:50 a.m. – 10:00 a.m.

Break

10:00 a.m. – 11:40 a.m.

Riverfront Room

Report from Prostate Cancer and Urological Cancers Collaborative Group

10:00 a.m. – 10:20 a.m.

Salient Report from the Chair/Co-Chair

10:20 a.m. – 10:40 a.m.

Presenter 1

10:40 a.m. – 11:00 a.m.

Presenter 2

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Thursday September 6, 2018 (Continued)

**Report from Prostate Cancer and Urological Cancers Collaborative Group
(Continued)**

- | | |
|--|---|
| <i>11:00 a.m. – 11:20 a.m.</i>
<i>Riverfront Room</i> | Presenter 3 |
| <i>11:20 a.m. – 11:40 a.m.</i> | Discussion of the Critical Questions <ul style="list-style-type: none">○ Collaborative Group Chair○ Member of the EDRN Executive Committee○ EDRN PI with content expertise (not necessarily the organ expertise) |
| 11:40 a.m. – 12:10 p.m. | <u>Towards Early Cancer Detection through EV Analysis</u>
Ralph Weissleder, M.D., Ph.D., Massachusetts General Hospital |
| 12:10 p.m. – 1:30 p.m. | Lunch (On Your Own) |
| 1:30 p.m. – 3:10 p.m.
<i>Riverfront Room</i> | <u>Report from Lung and Upper Aerodigestive Cancers Collaborative Group</u> |
| <i>1:30 p.m. – 1:50 p.m.</i> | Salient Report from the Chair/Co-Chair |
| <i>1:50 p.m. – 2:10 p.m.</i> | Presenter 1 |
| <i>2:10 p.m. – 2:30 p.m.</i> | Presenter 2 |
| <i>2:30 p.m. – 2:50 p.m.</i> | Presenter 3 |
| <i>2:50 p.m. – 3:10 p.m.</i> | Discussion of the Critical Questions <ul style="list-style-type: none">○ Collaborative Group Chair○ Member of the EDRN Executive Committee○ EDRN PI with content expertise (not necessarily with organ expertise) |
| 3:10 p.m. – 3:30 p.m. | Break |

**33rd EDRN Steering Committee Meeting
September 5-6, 2018
Royal Sonesta Boston
Cambridge, Massachusetts**

Thursday September 6, 2018 (Continued)

3:30 p.m. – 5:10 p.m.

Riverfront Room

Report from Breast and Gynecological Cancers Collaborative Group

3:30 p.m. – 3:50 p.m.

Salient Report from the Chair/Co-Chair

3:50 p.m. – 4:10 p.m.

Presenter 1

4:10 p.m. – 4:30 p.m.

Presenter 2

4:30 p.m. – 4:50 p.m.

Presenter 3

4:50 p.m. – 5:10 p.m.

Discussion of the Critical Questions

- Collaborative Group Chair
- Member of the EDRN Executive Committee
- EDRN PI with content expertise (not necessarily with organ expertise)

5:10 p.m. – 6:10 p.m.

Riverfront Room

General Discussion on EDRN Progress, Structure and Outlook

- Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute
- Arul Chinnaiyan, M.D., Ph.D., University of Michigan
- Joshua LaBaer, M.D., Ph.D., Arizona State University/The Biodesign Institute

6:10 p.m.

Adjourn